The elderly population is increasing worldwide. Despite a major decrease in deaths from coronary heart disease (CHD), this malady remains the major cause of death in elderly men and women. In this paper, we review the role of dyslipidemia as a major known risk factor in the pathogenesis of CHD, age-related changes in lipoprotein metabolism, and differences in changes in lipids that occur in men and women during aging. Next we provide an overview of the available studies and recommendations from ATP III. Finally, we comment on the screening and management, cost and side effects of therapy as it applies to an aging population.
Introduction
Prolongation of life is one of the most important accomplishments of medicine in the 20th century. Between the early 1900s and the beginning of the 21st century, lifespan increased from 60 to 85 years. At age 50 years or older, probability of dying has improved every year [Cristensen et al. 2009] . In developed countries, the population group older than 85 years is now the most rapidly expanding segment. Aging of population has been associated with a variety of new disease states. Although mortality from cardiovascular diseases has declined dramatically, the number of patients with cardiovascular diseases is increasing, probably because of survival of individuals with hypertension and diabetes as well as more frequent diagnosis. Here we discuss mainly the role of dyslipidemia, mainly abnormal low-density lipoprotein (LDL) cholesterol levels in aging.
Age-related changes in serum lipids in men and women After the age of 20 years, the LDL cholesterol concentrations increase progressively in men and women, but more rapidly in men, accounting for most of the overall gender difference in total cholesterol [Ferrara and Barrett-Connor, 1997; Ericsson et al. 1991] . The LDL cholesterol levels reach a plateau in men between the age of 50 and 60 years, and in women between the age of 60 and 70 years.
Serum high-density lipoprotein (HDL) cholesterol levels decrease in males during puberty and early adulthood, and thereafter remain lower than in women at all comparable ages. On the other hand, the HDL cholesterol concentrations remain constant in women throughout their lifetime [Kreisberg and Kasim, 1987] .
The triglyceride concentrations increase progressively in men, reaching peak values between 40 and 50 years of age, and decline slightly thereafter. In women, the triglyceride concentrations increase throughout their lifetime, and are always higher in those using estrogens.
Essentially before menopause, women usually have total cholesterol levels that are lower than those of men of the same age. As women and men get older, their blood cholesterol levels rise until about 60-65 years of age. In women, menopause often causes an increase in their LDL cholesterol and a decrease in their HDL cholesterol level, and after the age of 50, women often have higher total cholesterol levels than men of the same age [Kreisberg and Kasim, 1987] . This may well be one factor as to why the incidence of atherosclerotic disease rises dramatically in postmenopausal women. of the liver sinusoidal endothelial cells dysfunction. This physiologic phenomenon has been described in elderly humans and some animals. It leads to decreased endocytosis, increased leukocytes adhesion, decreased hepatic perfusion, and potentially affects passage of chylomicrons remnants to hepatocytes [Le Couteur et al. 2007] .
Dyslipidemia and coronary heart disease in the elderly Many studies have shown strong correlation between serum cholesterol levels and risk of developing coronary heart disease (CHD). Manolio and colleagues reviewed data from 22 cohort studies and showed that total cholesterol and LDL cholesterol levels were significantly associated with fatal CHD in both men and women in different age groups including older populations (>65 years) [Manolio et al. 1992 ]. Frost and colleagues reported similar findings in serum lipids and incidence of CHD from the Systolic Hypertension in the Elderly Program [Frost et al. 1996] . This study included a large number of men and women with a mean age of 72 years at entry followed for 4.5 years. They showed that the incidence of CHD events were increased by 2235% when non-HDL or LDL cholesterol levels increased by 1.03 mmol/l (40 mg/dl), and there was a 913% increase in the CHD event rate when non-HDL or LDL cholesterol levels increased by 10% (0.472 mmol/l for non-HDL and 0.398 for LDL).
Although the relative risk for developing CHD in persons with high cholesterol levels decreases with advanced age (>7580 years), high serum cholesterol levels still convey an increased risk for future cardiac events [Malenka and Baron, 1988] . It has been argued that the relative risk related to elevated serum cholesterol does not adequately predict the magnitude of CHD in the elderly because it does not take into account the high frequency of atherosclerosis in this age group. A more appropriate value appears to be attributable to risk between cohorts having high and low cholesterol levels; the risk probably reflects the impact of high cholesterol levels on the absolute incidence at a given age. In other words, elevated serum cholesterol is associated with a greater number of CHD events in the elderly than in the middle-aged or younger population. Consequently, reducing cholesterol concentration from high to low may well result in a greater overall reduction in new CHD events in older people than in middle-aged people, who generally have a lower absolute risk.
Despite the fact that most studies have shown a positive correlation between age, high cholesterol level and CHD risk, a recent study, the Copenhagen City Heart Study [Iverson et al. 2009] showed that this relationship does not necessarily apply to the elderly, 80 years or older. In another report [Anum and Adera, 2004 ], although a higher cholesterol level was associated with the all-cause mortality in people aged 65 years and above, this significant observation was not proven in persons older than 80 years.
Clinical data from several studies have consistently confirmed the high incidence of CHD events in subjects with metabolic syndrome. Elevated triglycerides and low HDL cholesterol levels are important part of this syndrome along with central obesity, high blood pressure and insulin resistance [Lindblad et al. 2001] . Metabolic syndrome affects 44% of the US population older than age 50, and affects more women than men. This age dependency of the syndrome prevalence is seen in spite of the fact that the body weight usually decreases in the elderly. It was noted though that the elderly are less sensitive to insulin than the younger population regardless of fat mass and fitness. The insulin resistance is, in part, related to decrease in content of glucose carrier protein in the muscle [Sawabe et al. 2009] . A decrease in insulin secretion may also contribute to insulin resistance and therefore higher incidence of metabolic syndrome in the elderly.
Some investigators have also invoked abnormalities in lipoprotein(a) (Lp(a)) levels in atherogenesis and the occurrence of CHD events. Lp(a) consists of a LDL particle bound to the plasminogen-like glycoprotein apolipoprotein(a). It has both pro-atherosclerotic and prothrombotic properties. It reflects a rather common genetic variation, and it is considered, by some, to be one of the genetic cardiovascular risks [Tziomalos et al. 2009] . There seems to be less emphasis on Lp(a) as a CHD risk factor, in part because of the fact that treatment of elevated Lp(a) is challenging, and statins, fibrates and fish oil have only modest effects [Maher et al. 1995] . Niacin can reduce Lp(a) levels by 2025%, and it was used in the Familial Atherosclerosis Treatment Study (FATS) , which demonstrated that reducing LDL cholesterol by 40% could eliminate the risk of elevated Lp(a) levels [Houmard et al. 1995] .
Secondary prevention of CHD events in the elderly
A meta-analysis of early trials, between the mid1960s and 1990, revealed that recurrent CHD events and mortality were significantly reduced by cholesterol-lowering therapy, with a strong trend toward a reduction in total mortality.
Although the association between hyperlipidemia and CHD was established much earlier [Benfante and Reed, 1990] , the demonstration of a relationship between a reduction in serum cholesterol levels and a reduction in all-cause mortality was confirmed after the introduction of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, or statins. Multiple randomized trials have since shown benefit of statins in both primary and secondary prevention of CHD events.
The results of major trails are presented in Table 1 , and the following paragraphs detail the salient points of major trials.
The Scandinavian Simvastatin Survival Study (4S) was the first secondary prevention trial that showed a clear 30% reduction in total mortality, driven largely by a 42% reduction in deaths from CHD. Patients older than 65 years taking simvastatin showed significantly fewer total deaths and major coronary events compared with placebo; those reductions paralleled those in patients younger than 65 years [Miettinen et al. 1997] .
The Cholesterol and Recurrent Events Trial (CARE) evaluated the effects of treatment with pravastatin in 4159 persons who had experienced Primary prevention of CHD events in the elderly As in secondary prevention trials, there is significant evidence of the benefits of statin therapy in the elderly population in primary prevention efforts.
The West of Scotland Coronary Prevention Study (WOSCOPS) demonstrated that treatment of men at relatively high risk with profoundly elevated cholesterol levels with pravastatin significantly reduced risk of CHD events [Shepherd et al. 1995] . Importantly, this study showed that the statin-treated group continued to experience lower rates of CHD events and death even after 10 years of additional follow up, even though only one third of patients continued to take statins. Older patients in WOSCOPS had similar reductions in CHD events as did the younger patients.
The Air Force/Texas Coronary Atherosclerosis Prevention Study (AF-CAPS/TexCAPS) in 1998 demonstrated a 36% risk reduction for first acute major coronary events in patients who were given lovastatin 2040 mg compared with placebo [Downs et al. 1998 ]. In this study, 22% of all patients were older than 65 years, and they responded similarly as did the younger patients in terms of risk reduction.
The Heart Protection Study (HPS) focused on patients who were at high risk for cardiovascular disease. Simvastatin therapy resulted in a 13% reduction in all-cause mortality, and an 18% reduction in coronary death rate [Heart Protection Study Collaborative Group, 2002] . This study provided evidence to support treatment of risk as endorsed by the National Cholesterol Education Program's (NCEP's) guidelines, and showed benefit of cholesterol reduction regardless of patient age at entry into the study.
Pravastatin in Elderly Individuals at risk of Vascular Disease (PROSPER) randomized 5804 patients between the age of 70 and 82 years to placebo or pravastatin [Shepherd et al. 2002] .
The study demonstrated a 15% reduction in the composite of coronary death, nonfatal myocardial infarction, and stroke over a period of 3 years. It also showed the benefit of cholesterol reduction in the elderly in primary and secondary event prevention much like the others.
The Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA) randomized 10,305 patients with hypertension and at least three other cardiovascular risk factors and a baseline mean LDL-C level of 133 mg/dl to atorvastatin 10 mg/day, or placebo. The analysis demonstrated marked benefit of statin therapy after only 1 year of treatment and the study was stopped earlier than planned [Sever et al. 2003 ]. This study, like HPS, showed the benefit of statin therapy in patients at high risk for cardiovascular disease regardless of age at entry.
Similarly, the Collaborative Atorvastatin Diabetes Study (CARDS) was terminated prematurely owing to a reduction on the primary endpoints (a composite of acute coronary events, coronary revascularization, or stroke) after a median follow up of 3.9 years [Neil et al. 2006] . The importance of this trial was its demonstration of major benefit of statin use in diabetic patients regardless of baseline LDL cholesterol level, and age.
Lipid-modifying therapy beyond statins
The issue of dyslipidemia beyond LDL cholesterol management has not been addressed in most previous trials. It is generally recognized that there are a large number of patients who are treated with statins, but have less than optimal levels of triglycerides and HDL cholesterol. It has been suggested that CHD events in patients with 'optimal' LDL cholesterol values may be due to these lipid abnormalities. However, the failure of the large clinical trial with the potent HDL cholesterol raising therapy with torcetrapib, a cholesteryl ester transfer protein (CETP) inhibitor, dampened the enthusiasm with regard to this approach.
It has been argued that adding agents that increase HDL cholesterol levels may improve surrogates of atherosclerosis, such as endothelial dysfunction, especially in diabetic patients [Sorrentino et al. 2010] . However, the nonstatin drugs, such as fibrates, niacin, or omega-3 fatty acids, have not shown a consistent effect on these surrogates. Nonetheless, these drugs have been shown to be effective in reducing coronary death and nonfatal myocardial infarction. Earlier trials in the nonstatin era showed that management of low HDL cholesterol and triglyceride levels with niacin caused an 11% reduction in all-cause mortality, mainly due to reduction in CHD mortality [Fruchart et al. 2008] . In the Coronary Drug Project [Berge and Canner, 1991] , the group that received niacin had a significant reduction (14%) in cardiac death and myocardial infarction over the 5-year period of observation. However, whether the benefits of these therapies extend to the elderly is not known. Further it is not known whether the effects of these therapies would be additive to the effects of statins.
Screening for and management of dyslipidemia
The NCEP ATP III recommends that fasting lipid panel should be measured at least once every 5 years in all adults 20 years of age and older without a history of CHD or other atherosclerotic diseases [Adult Treatment Panel III, 2002] . The clinical judgment and treatment recommendations based on Framingham risk score could be significantly different in the elderly. One important reason for this is the observation that advancing age by itself bears higher risk for CHD events, a reflection of multiple risk factors culminating in atherosclerosis. This fact points to the special consideration in adapting treatment guidelines to older persons [Grundy et al. 1999] .
Patients at highest risk of cardiovascular events are those with established CHD or evidence of atherosclerosis in noncoronary beds (i.e. abdominal aortic aneurysms, peripheral arterial disease, or symptomatic carotid disease), diabetes mellitus, or the presence of multiple risk factors conferring a calculated 10-year risk of more than 20%. The risk is calculated according to the Framingham risk score. The target LDL cholesterol level for this group is <100 mg/dl. Risk factors include age (men 45 years or older and women 55 years or older), smoking, hypertension (>140/90 mmHg or use of antihypertensive medication), family history of premature CHD (defined as CHD in first-degree male relatives before the age of 55 years and in a first-degree female relative before the age of 65 years), and low HDL cholesterol levels (<40 mg/dl).
The second category at high risk include patients with multiple risk factors and an estimated 10-year risk of adverse events between 10% and 20%. The target LDL cholesterol level for this group is <130 mg/dl.
The third category includes those with no or one risk factor and an estimated 10-year risk of <10%. The target LDL cholesterol level in this group is <160 mg/dl.
Nonpharmacological therapy for dyslipidemia in the elderly
The treatment of dyslipidemia requires two approaches, therapeutic lifestyle changes and medications. To achieve target LDL cholesterol levels, most patients need both approaches simultaneously. Lifestyle changes include a reduced intake of saturated fat (<7% of total calories) and cholesterol (<200 mg/day). Intake of transfatty acids should be kept to a minimum. Dietary calories should be derived predominantly from foods rich in complex carbohydrates, such as whole grains, fruit, and vegetables [Adult Treatment Panel III, 2002] . Daily intake of 510 g of viscous fiber reduces LDL cholesterol levels by approximately 5% and the use of plant stanols and sterols (23 g/day) by another 615%. Therapeutic lifestyle changes can achieve an almost 30% reduction in LDL cholesterol level in highly motivated individuals and should form the cornerstone of all preventive activity. LDL cholesterol should be measured 6 weeks after initiating a heart healthy diet, and if the goals are not met, intensification of lifestyle changes, use of plants sterols or stanols, referral to a dietitian for education and dietary counseling should be considered. If adequate control is not achieved in 3 months, drug therapy should be considered.
Given the balance of evidence in most trials and meta-analyses, a reasonable approach may be to initiate statin therapy in all patients with CHD or a CHD risk equivalent, regardless of baseline LDL cholesterol level, with a goal LDL cholesterol of <70 mg/dl for patients with CHD or at high risk of future CHD events. In patients with a 10-year risk of 1020%, an LDL cholesterol goal <100 mg/dl is reasonable, and initiation of statin therapy along with lifestyle change may be appropriate. This recommendation is based on the evidence from HPS and ASCOT-LLA. In individuals who have 10-year risk <10% and zero or one CHD risk factor, lifestyle change is recommended to achieve a target LDL cholesterol level of <160 mg/dl. If LDL cholesterol concentration remains >160 mg/dl after 3 months of lifestyle change, drug therapy may be considered. Pharmacotherapy is recommended in those with LDL cholesterol levels higher than 190 mg/dl.
Special considerations for management dyslipidemia in the elderly

Safety of LDL cholesterol-lowering therapy
The safety of lipid-lowering agents in the elderly was evaluated in two double-blind, placebo-controlled trials [LaRosa et al. 1994; Santinga et al. 1994] . The results showed that statin therapy was associated with a fall in cholesterol levels similar to that seen in younger subjects with no difference in side effects between the treatment and placebo groups.
It needs to be recognized that almost all trials of dyslipidemia therapy lasted for a maximum of 5 years. In the real world, the therapy with statins, niacin, or fibrates is continued indefinitely. Intake of chemicals, whether natural or synthetic, for a long period of time may have unforeseen consequences. In a recent study in 350,000 veteran patients, statin treatment was shown to increase fasting blood glucose in diabetics, as well as nondiabetic US veteran patients [Sukhija et al. 2009] . A recent meta-analysis also showed a significant 9% increase risk for incident diabetes in the patients taking statins [Sattar et al. 2010] . This risk of developing diabetes with statins was highest in trials with older individuals. Therefore, whether the benefit of statin therapy in elderly patients overrides this risk is something to be considered.
Cost benefits of management oh high LDL cholesterol
It is important to note that medical and surgical management of CHD in the elderly make up a major component of healthcare cost. In the 4S, CARE, and LIPID trials, reducing serum cholesterol levels provided substantial reductions in the need for coronary artery bypass surgery and coronary angioplasty [Miettinen et al. 1997; Sacks et al. 1996; Benfante and Reed, 1990] . Moreover, various analyses [Miettinen et al. 1997] reveal that aggressive reduction on serum cholesterol levels in patients with established CHD reduces both morbidity and mortality at low cost.
Recent costbenefit analysis from HPS demonstrated that at a daily cost of US$1 for a 40 mg generic simvastatin tablet, the estimated cost of preventing a vascular death within the 5-year period results in a net saving of US$1300 to US$216,500 depending on the patients' 5-year major CHD event risk. The costs per life year gained with lifetime simvastatin treatment ranges from US$2500 in individuals 4049 years of age with a 42% 5-year major cardiovascular event risk to US$10,990 in individuals 70 years and older with a 12% 5-year cardiovascular event risk [Heart Protection Study Collaborative Group, 2009] .
How aggressively to treat LDL cholesterol?
The aggressiveness of cholesterol testing and treatment must be tempered by clinical judgment. To date, no data are available to define which subgroups of the elderly with CHD will benefit from aggressive cholesterol management. While therapeutic lifestyles measures are encouraged in the elderly, some patients are still at high risk for CHD and may be candidates for drug therapy. Further, one should avoid dietary restrictions in elderly patients who are at high risk of malnutrition, especially in patients with dementia or physical disabilities that limit their access to adequate nutrition.
Interactions of dyslipidemia therapy with other drugs and disease states One should also be aware of the interactions of lipid-modifying drugs with other medications, particularly in the elderly who are frequently treated with multiple drugs. These patients often are on antiplatelet agents and anticoagulants, whose efficacy may be markedly altered with lipid-modifying agents [Lau et al. 2003 ]. These agents also interact with some anti-arrhythmic drugs and antibiotics, probably because of hepatic metabolism of these agents [Merz and Fuller, 2007] . There are also anecdotal reports of loss of memory and other cognitive functions with excessive cholesterol lowering [Wagstaff et al. 2003 ].
Results of three large studies (ENHANCE, SEAS, and ARBITER-6) showed that cholesterol lowering with statins is reasonable and results in a decrease in intima-media thickness, a surrogate marker of CHD [Taylor et al. 2009] . However, these studies have also dampened the enthusiasm for all cholesterol-lowering drugs since LDL cholesterol lowering with ezetemibe was not associated with similar decrease in intima-media thickness as statins. Although the elderly population was not specifically looked at, there is a reason for greater caution for use of unproven strategies in the elderly who may have underlying compromise of liver and renal functions.
Because the prevalence of chronic kidney disease (CKD) increases with age, it is essential to adjust the dosages of some lipid-lowering agents. Most statins have hepatic elimination and the renal route is usually a minor elimination pathway. However, when creatinine clearance is <30 ml/ min (CKD stage 4 and 5), atorvastatin and fluvastatin may be preferred since their dosages do not need to be modified in renal dysfunction. On the other hand, pravastatin and simvastatin doses may need to be lowered [Launay-Vacher et al. 2005] .
Special considerations for management of dyslipidemia in elderly women Lipid management has received less attention in elderly women because their age at onset of CHD events tends to be later than in men; and premature CHD is very unusual in women. Some investigators argue that high serum cholesterol is not a major risk factor in elderly women. However, CHD is a major health problem in both men and women, and its prevention deserves high priority. ATP III recommends the same guidelines to be used for management of high serum cholesterol in elderly women as in men. This similarity in guidelines extends to dietary therapy, weight control, and physical activity, as well as drug therapy. Previously, some studies in postmenopausal women strongly suggested that estrogen replacement therapy would reduce the risk of CHD and osteoporosis, as well as lower LDL cholesterol levels [Neil et al. 2006] .
However, the Heart and Estrogen/progestin Replacement Study (HERS) showed that hormone replacement therapy may not reduce overall CHD events, and may increase the rate of thrombotic events and gallbladder disease [Sorrentino et al. 2010] . This negative finding along with the positive results of statin trials suggest that statin drugs should be used instead of estrogens by high-risk women in whom drug therapy is considered necessary to lower their CHD risk.
Conclusion
Owing to the similar pathways of pathogenesis of CHD in middle-aged and older patients, it is wise to manage hyperlipidemia in a similar manner as in younger patients. The elderly group carries the highest risk for CHD and the highest burden of atherosclerotic disease. The results of many trials for secondary prevention support the inclusion of the elderly in cholesterol management. The first line of primary prevention is still therapeutic lifestyle change, including regular physical activity and weight control, statin therapy can and should be considered for patients at high risk.
Although there are many special considerations for lipid management in the elderly patients, especially with regard to diet restriction, drugs side effects, and drug interactions, the treatment of dyslipidemia in elderly is both achievable and beneficial regardless of the starting age and, it can be cost effective.
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